RAS inhibitors in hematologic cancers: Biologic considerations and clinical applications
RAS inhibitors in hematologic cancers: Biologic considerations and clinical applications
复制标题
DOI：
10.1023/a:1006319116226
复制
发表时间：
1999-05-01
影响因子：
3.4
通讯作者：
Kurzrock, R
中科院分区：
文献类型：
--
作者：
Beaupre, DM;Kurzrock, R
随着癌症发生和传播的分子机制逐渐被阐明，治疗方法也随之出现。最近，一些研究人员描述了 Ras 蛋白的抑制剂。该分子已成为靶点，因为 RAS 是人类肿瘤中最常见的突变癌基因之一。在这篇综述中，我们将讨论 Ras 在血液肿瘤发病机制中的作用，以及开发特异性抑制 Ras 功能的新型化合物背后的生物学原理。
As the molecular mechanisms responsible for the development and propagation of cancer are becoming elucidated, therapy is emerging. Recently, several investigators have described inhibitors of the Ras protein. This molecule has been targeted because RAS is one of the most commonly mutated oncogenes in human neoplasia.In this review, we will discuss the role of Ras in the pathogenesis of hematologic neoplasms, and the biology behind the development of novel compounds which specifically suppress Ras function.